Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian03 maintenance trial of raludotatug deruxtecan with or without bevacizumab versus standard of care
jRCT2031260346Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Arm 1: R-DXd Alone or R-DXd Combined with Bevacizumab with Arm 2: Bevacizumab Alone or Observation (2 arms). Primary endpoint: Progression-free survival by blinded independent central review per RECIST v1.1. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2031260346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260346.